DEFINITIVE LE Atherectomy Trial Subset Analysis

At the 5th Annual Amputation Prevention Symposium, Vascular Disease Management asked Lawrence A. Garcia, MD, to share details about subset analysis and new insights from the DEFINITIVE LE trial. The DEFINITIVE LE study was conducted at 47 sites in Europe and the United States to assess use of directional atherectomy using the SilverHawk and TurboHawk Plaque Excision Systems (Covidien). The study enrolled 800 patients with PAD in the superficial femoral, infrapopliteal and popliteal arteries. Dr. Garcia and colleagues recently published a subset analysis comparing patients with and without diabetes.